Megestrol acetate (MA) may safely increase serum albumin in malnourished dialysis patients, according to researchers in Iran.
Ali Monfared, MD, and colleagues at the Guilan University of Medical Science in Rasht tested the medication in 22 malnourished dialysis patients with persistent hypoalbuminemia (albumin level less than 3.5 g/dL for two months).
They randomized subjects to receive MA 40 mg twice daily over two months or not to receive this treatment (controls). After two months, the mean serum albumin level in the MA group rose from 3.31 to 4.41 g/dL, whereas it declined in the control arm from 3.35 to 3.02 g/dL, a significant difference between the groups, the investigators reported in the Journal of Renal Nutrition (2009;19:167-171).
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.